Lazard Asset Management
TXG icon

Lazard Asset Management’s 10x Genomics TXG Stock Holding History

Lazard Asset Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.52M Sell
91,873
-91,111
-50% -$2.39M 0.01% 738
2026
Q1 		$3.88M Sell
182,984
-45,761
-20% -$915K 0.01% 640
2025
Q4 		$3.73M Buy
228,745
+102,133
+81% +$1.54M 0.01% 646
2025
Q3 		$1.48M Buy
126,612
+23,813
+23% +$310K ﹤0.01% 980
2025
Q2 		$1.19M Sell
102,799
-7,547
-7% -$68.8K ﹤0.01% 1228
2025
Q1 		$963K Sell
110,346
-16,154
-13% -$204K ﹤0.01% 1231
2024
Q4 		$1.82M Sell
126,500
-22,552
-15% -$356K ﹤0.01% 919
2024
Q3 		$3.36M Buy
149,052
+80,953
+119% +$1.67M ﹤0.01% 732
2024
Q2 		$1.32M Sell
68,099
-6,441
-9% -$169K ﹤0.01% 920
2024
Q1 		$2.8M Buy
74,540
+13,972
+23% +$614K ﹤0.01% 788
2023
Q4 		$3.39M Sell
60,568
-1,743
-3% -$75.8K ﹤0.01% 762
2023
Q3 		$2.57M Sell
62,311
-37,141
-37% -$1.93M ﹤0.01% 828
2023
Q2 		$5.55M Buy
99,452
+838
+0.8% +$45.4K 0.01% 686
2023
Q1 		$5.5M Sell
98,614
-269
-0.3% -$12.6K 0.01% 708
2022
Q4 		$3.6M Sell
98,883
-34,585
-26% -$1.13M 0.01% 791
2022
Q3 		$3.8M Buy
133,468
+6,393
+5% +$244K 0.01% 761
2022
Q2 		$5.75M Buy
127,075
+57,291
+82% +$2.97M 0.01% 707
2022
Q1 		$5.31M Buy
69,784
+16,550
+31% +$1.45M 0.01% 745
2021
Q4 		$7.93M Buy
53,234
+27,425
+106% +$4.2M 0.01% 690
2021
Q3 		$3.76M Buy
25,809
+1,212
+5% +$208K ﹤0.01% 817
2021
Q2 		$4.82M Buy
24,597
+24,265
+7,309% +$4.39M 0.01% 732
2021
Q1 		$60K Buy
332
+16
+5% +$2.76K ﹤0.01% 1368
2020
Q4 		$44K Buy
+316
New +$45.9K ﹤0.01% 1426

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Lazard Asset Management's TXG Position: Q2 2026 in Review

Lazard Asset Management reduced its 10x Genomics (TXG) stake by 50% in Q2 2026, selling an estimated $2.39M and leaving 91,873 shares worth $3.52M. The position accounts for 0.01% of the portfolio, ranked #738.

Lazard Asset Management first reported a position in TXG in Q4 2020 and has held it in 23 quarters since. The position peaked at $7.93M in Q4 2021. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Lazard Asset Management held 91,873 shares of 10x Genomics worth $3.52M as of Q2 2026.
  • Lazard Asset Management sold 91,111 10x Genomics shares in Q2 2026, an estimated $2.39M.
  • 10x Genomics made up 0.01% of Lazard Asset Management's portfolio in Q2 2026, its #738 holding.
  • Lazard Asset Management first reported a position in 10x Genomics in Q4 2020 and has held it in 23 quarters since.
  • Lazard Asset Management's 10x Genomics position peaked at $7.93M in Q4 2021.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.